Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer

NCT ID: NCT02761512


Title
A Double Blind, Randomized, Active-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer
Purpose
To demonstrate non-inferiority of CJ-12420 to lansoprazole 30 mg capsule in terms of therapeutic efficacy, and to confirm safety of CJ-12420, after once daily oral administration of CJ-12420 50 mg, 100 mg or Lansoprazole 30 mg capsule in gastric ulcer patients.
Details
This is a double blind, randomized, placebo-controlled, phase 3 study. Subjects will be randomly assigned to one of the three treatment groups (CJ-12420 50 mg, 100 mg or Lansoprazole 30 mg).
Conditions
Gastric Ulcer
Keywords
Source
CJ HealthCare Corporation
Sponsors
CJ HealthCare Corporation
Status
Recruiting
Acronym
Last Updated
27 Dec 2016
URL
Official Link
Locations
Korea, Republic of